Patients with acute myeloid leukemia (AML) face unique challenges related to social determinants of health that significantly impact their treatment access and outcomes. Geographic distance from specialized treatment centers creates substantial barriers, as patients require frequent monitoring, blood transfusions, and urgent medical attention throughout their treatment course. Unlike solid tumor patients who might visit clinic every few weeks, AML patients often need care multiple times weekly, making transportation and proximity to treatment facilities critical factors in treatment success.
The intensive nature of AML care creates particular hardships for patients with limited social support, inadequate housing, or financial constraints. Patients must navigate complex treatment regimens while managing the physical and emotional stress of a life-threatening diagnosis, often becoming primary caregivers’ full-time responsibility. The immunocompromised state that results from both the disease and its treatment requires patients to limit social interactions and maintain strict infection precautions, leading to isolation that can significantly impact mental health and treatment adherence.
Health care teams increasingly recognize that addressing social determinants requires comprehensive support beyond medical treatment alone. Patients benefit from early integration of palliative care services to help manage symptoms, reduce anxiety, and improve quality of life throughout the treatment journey. Sexual health concerns, while understudied in leukemia patients, represent an important quality of life issue that deserves attention and support. Successful AML care requires coordinated efforts to address transportation barriers, provide psychosocial support, ensure adequate nutrition, and maintain patients’ connection to their support systems while managing the demands of intensive treatment protocols.
Social Determinants to AML Treatment Approach
Amer Zeidan, MBBS, MHS
Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation access, health literacy, and the intensive nature of treatment requiring frequent clinic visits for blood work and transfusions, which disproportionately affects patients living far from treatment centers.
EP: 1.Overview of Pathophysiology of and Progression of AML
EP: 2.Risk Classification Systems in AML
EP: 3.Key Patient Factors to Consider in AML Treatment Decisions
EP: 4.Provider Perspectives on Biggest Unmet Needs in AML Care
EP: 5.Social Determinants to AML Treatment Approach
EP: 6.Latest NCCN Guidelines on the Standard of Care for Patients With AML
Patients with acute myeloid leukemia (AML) face unique challenges related to social determinants of health that significantly impact their treatment access and outcomes. Geographic distance from specialized treatment centers creates substantial barriers, as patients require frequent monitoring, blood transfusions, and urgent medical attention throughout their treatment course. Unlike solid tumor patients who might visit clinic every few weeks, AML patients often need care multiple times weekly, making transportation and proximity to treatment facilities critical factors in treatment success.
The intensive nature of AML care creates particular hardships for patients with limited social support, inadequate housing, or financial constraints. Patients must navigate complex treatment regimens while managing the physical and emotional stress of a life-threatening diagnosis, often becoming primary caregivers’ full-time responsibility. The immunocompromised state that results from both the disease and its treatment requires patients to limit social interactions and maintain strict infection precautions, leading to isolation that can significantly impact mental health and treatment adherence.
Health care teams increasingly recognize that addressing social determinants requires comprehensive support beyond medical treatment alone. Patients benefit from early integration of palliative care services to help manage symptoms, reduce anxiety, and improve quality of life throughout the treatment journey. Sexual health concerns, while understudied in leukemia patients, represent an important quality of life issue that deserves attention and support. Successful AML care requires coordinated efforts to address transportation barriers, provide psychosocial support, ensure adequate nutrition, and maintain patients’ connection to their support systems while managing the demands of intensive treatment protocols.
Experts, Patients Highlight Barriers to Arthritis Care Amid World Arthritis Day Observance
October 14th 2025Arthritis care remains fragmented and costly, with access disparities prompting calls for preventive strategies, community resources, and systemic improvements.
Read More
The Emerging Landscape of GLP-1 RA Therapies Across Conditions
October 14th 2025The founder and CEO of Phesi addresses the need for streamlining clinical trial data as GLP-1 RA therapies are being used to treat multiple diseases.
Listen
5 Rare Types of Arthritis
October 10th 2025Arthritis is not one disease, and it has an impact that extends far beyond the well-known osteoarthritis or rheumatoid arthritis.
Read More
Dr Anders Kolb on Leading Blood Cancer United Into a New Era
September 25th 2025Blood Cancer United, formerly Leukemia & Lymphoma Society, aims to enhance awareness and support for blood cancer patients during Blood Cancer Awareness Month.
Listen
Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis
October 9th 2025Efgartigimod shows promising efficacy over IV immunoglobulin in treating impending myasthenic crisis in patients with myasthenia gravis.
Read More
CDC Reports Largest Pediatric Influenza-Associated Encephalopathy Case Series in 2024-2025 Season
October 9th 2025US pediatric influenza-associated encephalopathy (IAE) cases surged during the 2024-2025 season, highlighting severe health risks and the need for better surveillance.
Read More
Experts, Patients Highlight Barriers to Arthritis Care Amid World Arthritis Day Observance
October 14th 2025Arthritis care remains fragmented and costly, with access disparities prompting calls for preventive strategies, community resources, and systemic improvements.
Read More
The Emerging Landscape of GLP-1 RA Therapies Across Conditions
October 14th 2025The founder and CEO of Phesi addresses the need for streamlining clinical trial data as GLP-1 RA therapies are being used to treat multiple diseases.
Listen
5 Rare Types of Arthritis
October 10th 2025Arthritis is not one disease, and it has an impact that extends far beyond the well-known osteoarthritis or rheumatoid arthritis.
Read More
Dr Anders Kolb on Leading Blood Cancer United Into a New Era
September 25th 2025Blood Cancer United, formerly Leukemia & Lymphoma Society, aims to enhance awareness and support for blood cancer patients during Blood Cancer Awareness Month.
Listen
Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis
October 9th 2025Efgartigimod shows promising efficacy over IV immunoglobulin in treating impending myasthenic crisis in patients with myasthenia gravis.
Read More
CDC Reports Largest Pediatric Influenza-Associated Encephalopathy Case Series in 2024-2025 Season
October 9th 2025US pediatric influenza-associated encephalopathy (IAE) cases surged during the 2024-2025 season, highlighting severe health risks and the need for better surveillance.
Read More